IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Naturland Holding PLC A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.	United Kingdom	NATUR
NEKTAR THERAPEUTICS Biopharma developing innovative medicines for autoimmune and inflammatory conditions.	United States of America	NKTR
NEOGEN CORP Provides diagnostic tests and genomics services for food, animal, and agricultural safety.	United States of America	NEOG
NEOGENOMICS INC Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.	United States of America	NEO
NeoImmuneTech, Inc. Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.	United States of America	950220
NEONC TECHNOLOGIES HOLDINGS, INC. Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.	United States of America	NTHI
Neumora Therapeutics, Inc. Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.	United States of America	NMRA
Neuphoria Therapeutics Inc. Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.	United States of America	NEUP
NEUROCRINE BIOSCIENCES INC Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.	United States of America	NBIX
Neurogene Inc. Developing genetic medicines using gene therapy for rare and devastating neurological diseases.	United States of America	NGNE